Compile Data Set for Download or QSAR
Report error Found 26 Enz. Inhib. hit(s) with all data for entry = 50014546
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM50577248(CHEMBL4878379 | US20240239774, Example 33)
Affinity DataIC50: 28nMAssay Description:Inhibition of human soluble adenylyl cyclase assessed as reduction in cAMP levels in the presence of alpha-32p labeled ATP by biochemical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM50577241(CHEMBL4848035 | US20240239774, Example 2)
Affinity DataIC50: 74nMAssay Description:Inhibition of human soluble adenylyl cyclase assessed as reduction in cAMP levels in the presence of alpha-32p labeled ATP by biochemical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM50577242(CHEMBL4854762 | US20240239774, Example 1)
Affinity DataIC50: 92nMAssay Description:Inhibition of human soluble adenylyl cyclase transfected (4-4 clones)in human HEK293 cells assessed as reduction in cAMP levels preincubated for 5 mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM50577241(CHEMBL4848035 | US20240239774, Example 2)
Affinity DataIC50: 102nMAssay Description:Inhibition of human soluble adenylyl cyclase transfected (4-4 clones)in human HEK293 cells assessed as reduction in cAMP levels preincubated for 5 mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM50577243(CHEMBL4868801 | US20240239774, Example 19)
Affinity DataIC50: 107nMAssay Description:Inhibition of human soluble adenylyl cyclase assessed as reduction in cAMP levels in the presence of alpha-32p labeled ATP by biochemical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM50577244(CHEMBL4864668 | US20240239774, Example 20)
Affinity DataIC50: 126nMAssay Description:Inhibition of human soluble adenylyl cyclase assessed as reduction in cAMP levels in the presence of alpha-32p labeled ATP by biochemical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM50577236(CHEMBL4857305 | US20240239774, Example 17)
Affinity DataIC50: 132nMAssay Description:Inhibition of human soluble adenylyl cyclase assessed as reduction in cAMP levels in the presence of alpha-32p labeled ATP by biochemical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM50577232(CHEMBL4849033 | US20240239774, Example 16)
Affinity DataIC50: 141nMAssay Description:Inhibition of human soluble adenylyl cyclase assessed as reduction in cAMP levels in the presence of alpha-32p labeled ATP by biochemical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM50577242(CHEMBL4854762 | US20240239774, Example 1)
Affinity DataIC50: 195nMAssay Description:Inhibition of human soluble adenylyl cyclase assessed as reduction in cAMP levels in the presence of alpha-32p labeled ATP by biochemical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM50577232(CHEMBL4849033 | US20240239774, Example 16)
Affinity DataIC50: 196nMAssay Description:Inhibition of human soluble adenylyl cyclase transfected (4-4 clones)in human HEK293 cells assessed as reduction in cAMP levels preincubated for 5 mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM50577233(CHEMBL4874288 | US20240239774, Example 14)
Affinity DataIC50: 225nMAssay Description:Inhibition of human soluble adenylyl cyclase transfected (4-4 clones)in human HEK293 cells assessed as reduction in cAMP levels preincubated for 5 mi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM50577245(CHEMBL4866319 | US20240239774, Example 24)
Affinity DataIC50: 325nMAssay Description:Inhibition of human soluble adenylyl cyclase assessed as reduction in cAMP levels in the presence of alpha-32p labeled ATP by biochemical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM50577234(CHEMBL4864843 | US20240239774, Example 12)
Affinity DataIC50: 342nMAssay Description:Inhibition of human soluble adenylyl cyclase assessed as reduction in cAMP levels in the presence of alpha-32p labeled ATP by biochemical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM50577235(CHEMBL4867202 | US20240239774, Example 25)
Affinity DataIC50: 351nMAssay Description:Inhibition of human soluble adenylyl cyclase assessed as reduction in cAMP levels in the presence of alpha-32p labeled ATP by biochemical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM50577233(CHEMBL4874288 | US20240239774, Example 14)
Affinity DataIC50: 392nMAssay Description:Inhibition of human soluble adenylyl cyclase assessed as reduction in cAMP levels in the presence of alpha-32p labeled ATP by biochemical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM50577238(CHEMBL4866035 | US20240239774, Example 27)
Affinity DataIC50: 576nMAssay Description:Inhibition of human soluble adenylyl cyclase assessed as reduction in cAMP levels in the presence of alpha-32p labeled ATP by biochemical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM50577249(CHEMBL4878049 | US20240239774, Example 34)
Affinity DataIC50: 700nMAssay Description:Inhibition of human soluble adenylyl cyclase assessed as reduction in cAMP levels in the presence of alpha-32p labeled ATP by biochemical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM50577237(CHEMBL4874934 | US20240239774, Example 4)
Affinity DataIC50: 989nMAssay Description:Inhibition of human soluble adenylyl cyclase assessed as reduction in cAMP levels in the presence of alpha-32p labeled ATP by biochemical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM50577240(CHEMBL4847756)
Affinity DataIC50: 1.00E+3nMAssay Description:Inhibition of human soluble adenylyl cyclase assessed as reduction in cAMP levels in the presence of alpha-32p labeled ATP by biochemical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM50577239(CHEMBL4862670)
Affinity DataIC50: 1.00E+3nMAssay Description:Inhibition of human soluble adenylyl cyclase assessed as reduction in cAMP levels in the presence of alpha-32p labeled ATP by biochemical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM492902(US10981899, Example RU-0204277-LRE1)
Affinity DataIC50: 1.50E+3nMAssay Description:Inhibition of human soluble adenylyl cyclase assessed as reduction in cAMP levels in the presence of alpha-32p labeled ATP by biochemical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM50577251(CHEMBL4870637 | US20240239774, Example 45)
Affinity DataIC50: 1.64E+3nMAssay Description:Inhibition of human soluble adenylyl cyclase assessed as reduction in cAMP levels in the presence of alpha-32p labeled ATP by biochemical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM50577247(CHEMBL4874074 | US20240239774, Example 74)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of human soluble adenylyl cyclase assessed as reduction in cAMP levels in the presence of alpha-32p labeled ATP by biochemical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM50577246(CHEMBL4851867)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of human soluble adenylyl cyclase assessed as reduction in cAMP levels in the presence of alpha-32p labeled ATP by biochemical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM50577250(CHEMBL4868259)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of human soluble adenylyl cyclase assessed as reduction in cAMP levels in the presence of alpha-32p labeled ATP by biochemical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed
TargetAdenylate cyclase type 10(Human)
Tri-Institutional Institutional Therapeutics Discovery Institute

Curated by ChEMBL
LigandPNGBDBM50577252(CHEMBL4854260)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of human soluble adenylyl cyclase assessed as reduction in cAMP levels in the presence of alpha-32p labeled ATP by biochemical assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2022
Entry Details Article
PubMed